Vital Therapies, Inc. (NASDAQ:VTL) is scheduled to release its Q3 2017 earnings data after the market closes on Wednesday, November 1st. Analysts expect Vital Therapies to post earnings of ($0.32) per share for the quarter.

Vital Therapies (NASDAQ:VTL) last announced its earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. During the same quarter in the previous year, the business posted ($0.30) EPS. On average, analysts expect Vital Therapies to post $-1.29 EPS for the current fiscal year and $-1.39 EPS for the next fiscal year.

Vital Therapies, Inc. (NASDAQ:VTL) opened at 5.50 on Wednesday. The firm’s 50-day moving average is $4.94 and its 200 day moving average is $3.57. Vital Therapies, Inc. has a 52 week low of $2.25 and a 52 week high of $6.50. The stock’s market cap is $232.14 million.

In other news, Director Muneer A. Satter bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was acquired at an average price of $3.53 per share, with a total value of $176,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Jacques Bienaime bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were purchased at an average cost of $4.00 per share, with a total value of $40,000.00. Following the purchase, the director now directly owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. Insiders have bought 190,000 shares of company stock worth $737,800 over the last three months. Corporate insiders own 32.60% of the company’s stock.

A number of analysts recently issued reports on the stock. ValuEngine raised shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Finally, BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $8.00.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Earnings History for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with's FREE daily email newsletter.